Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly (GARLIT)
Latest Information Update: 06 Mar 2023
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Acronyms GARLIT
- 26 Dec 2022 Results assessing the maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients (n=191), published in the European Journal of Neurology
- 01 Nov 2022 Results published in the Journal of Neurology
- 01 Apr 2022 Results (n=156)published in the European Journal of Neurology